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ReviewInflammation in Neurodegenerative
Disease—A Double-Edged Sword
emanating from injured neurons, or by imbalances be-
tween pro- and antiinflammatory processes.
Inflammatory responses also recruit immune mecha-
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University of California, San Francisco nisms, and a growing number of studies are discovering
intriguing links between the immune system and theSan Francisco, California 94141
CNS. For example, various immune cells can traverse
the blood-brain barrier, although the CNS is partially
sheltered from immune surveillance. During CNS devel-Inflammation is a defense reaction against diverse in-
sults, designed to remove noxious agents and to in- opment, blood-derived monocytes populate the brain
to form microglia, and activated lymphocytes can crosshibit their detrimental effects. It consists of a dazzling
array of molecular and cellular mechanisms and an the intact blood-brain barrier even in adults (Hickey,
2001). Invading lymphocytes can attack target antigensintricate network of controls to keep them in check.
In neurodegenerative diseases, inflammation may be in the CNS or produce growth factors that might protect
neurons against degeneration (Schwartz et al., 1999;triggered by the accumulation of proteins with abnor-
mal conformations or by signals emanating from in- Hohlfeld et al., 2000). Immune molecules such as Thy-1,
interleukins, and chemokines are expressed at high lev-jured neurons. Given the multiple functions of many
inflammatory factors, it has been difficult to pinpoint els in neurons and may be involved in the communica-
tion of neurons with glial cells (Leyton et al., 2001; Allantheir roles in specific (patho)physiological situations.
Studies of genetically modified mice and of molecular and Rothwell, 2001). Molecules mediating specific anti-
gen recognition by T lymphocytes, including major his-pathways in activated glia are beginning to shed light
on this issue. Altered expression of different inflamma- tocompatibility complex (MHC) class I and CD3 mole-
cules, also have a role in activity-dependent remodelingtory factors can either promote or counteract neuro-
degenerative processes. Since many inflammatory re- and plasticity in the developing and mature mammalian
CNS (Boulanger et al., 2001).sponses are beneficial, directing and instructing the
inflammatory machinery may be a better therapeutic There are three common outcomes of inflammation.
The offending agent or process is inactivated and theobjective than suppressing it.
injury repaired. The host loses the battle and dies or
suffers irreparable tissue damage. Neither the organismMore than a century ago, Elias Metchnikoff, one of the
founders of cellular immunology, discovered that ame- nor the injurious process prevails, resulting in a pro-
longed battle that provides fertile ground for the devel-boid cells of starfish larvae can devour foreign objects
and digest cellular debris, leading him to postulate that opment of chronic inflammatory conditions. The last
outcome may relate closely to neurodegenerative dis-phagocytes are inflammatory cells with beneficial func-
tions (Metchnikoff, 1884). This hypothesis was soon eases, one of the greatest public health problems of this
century (Cowan and Kandel, 2001).challenged by some of his contemporaries, who main-
tained that phagocytes are themselves the perpetrators In this Review, we will examine the role of inflamma-
tion in neurodegenerative diseases. First, we will discussof inflammatory disease (Tauber, 1992). Scientists today
face a similar dilemma in trying to decipher the role some of the CNS alterations that could trigger inflamma-
tory responses in these conditions. Second, we will re-of inflammatory responses in the degenerating central
nervous system (CNS), since many of these responses view the main components of inflammatory responses
in the CNS, which include both innate and acquiredmight either promote or inhibit the neurodegenerative
process (Figure 1). immune mechanisms. Third, we will highlight how diffi-
cult it is to pinpoint the specific role of multifunctionalInflammation is an active defense reaction of multicel-
lular organisms against diverse insults, designed to re- inflammatory mediators in different pathophysiological
situations. Fourth, we will discuss the potential of manip-move or inactivate noxious agents and to inhibit and
reverse their detrimental effects. It typically consists of ulating inflammatory responses as a therapeutic strat-
egy in neurodegenerative disorders.multiple components and should not be simply equated
with the infiltration of tissues by blood-derived immune
cells, since such infiltration only represents one particu- Triggers of Inflammation
lar type of inflammatory response. Inflammation can be in Neurodegenerative Disease
triggered by invading microbes such as viruses and bac- Crucial to the activation of inflammatory responses in a
teria, as well as by injurious chemicals or physical in- tissue is the sensing by host defense mechanisms of a
sults. It can also be initiated from within the organism, noxious agent or an injurious process. The ability to
for example, by diseases affecting the immune system distinguish foreign from self and abnormal from normal
or the nervous system. In neurodegenerative diseases, is among the most fascinating aspects of inflammation
inflammation may be triggered by the accumulation of in the CNS and elsewhere. A dazzling array of molecular
aggregated or otherwise modified proteins, by signals and cellular mechanisms has evolved to carry out these
tasks, and we are only beginning to understand the
intricate network of controls that keep these systems1 Correspondence: twysscoray@gladstone.ucsf.edu (T.W.-C), lmucke@
gladstone.ucsf.edu (L.M.) in check.
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inflammatory pathways. For example, A can trigger
microglial activation by binding to the receptor for ad-
vanced glycation end products (RAGE) (Yan et al., 1999)
or other scavenger receptors (Paresce et al., 1996; El
Khoury et al., 1996), and at least some of these pathways
seem to involve the CD40 signaling receptor (Tan et al.,
1999). A fibrils also bind to RAGE on neurons, causing
cellular stress and the release of inflammatory factors
(Yan et al., 1999). Aggregated A can activate the com-
plement system in vitro through the classical pathway
by binding C1q and through the alternative pathway by
binding C3b (Rogers et al., 1992; Webster et al., 1997a;
Bradt et al., 1998). Complement was also activated by
neurofibrillary tangle preparations isolated postmortemFigure 1. The Inflammatory Response as an Indicator and Potential
from human AD brains (Shen et al., 2001). Treatment ofModulator of Neurodegeneration
neurons with proteasome inhibitors elicited accumula-Neurodegenerative processes culminate in cell death and are often
tion of ubiquinated proteins and increased neuronal pro-associated with innate and acquired immune responses (partial list-
duction of cyclooxygenase (COX) 2 and proinflammatorying). These inflammatory responses probably aim to remove the
pathogenic trigger and inhibit the neurodegenerative process. How- prostaglandins (Rockwell et al., 2000), suggesting that
ever, uncontrolled or chronic inflammation may also promote this the production of inflammatory mediators can be trig-
process. CD, cluster of differentiation; MHC, major histocompatibil- gered not only by extracellular protein deposits but also
ity complex; NK, natural killer; TCR, T cell receptor. ↓, stimulation;
by the intracellular accumulation of abnormal proteins.⊥, inhibition.
Aging is associated with glial activation, increased
production of inflammatory mediators, accumulation of
modified proteins and lipids, and neuronal deficits (Mas-Inflammation in neurodegenerative disorders might
liah et al., 1993; West et al., 1994; Jucker and Ingram,result from a number of causes: protein aggregates,
1997; Morgan et al., 1999). A comparison of 5- and 30-accumulation of other abnormally modified cellular con-
month-old mice revealed a prominent increase in thestituents, molecules released from or associated with
expression of many inflammatory and stress genes ininjured neurons or synapses, and dysregulation of in-
the aged mice, including complement factors, glial acti-flammatory control mechanisms (Figure 1). The resulting
vation markers, cyclophilin, and heat shock proteinsinflammatory responses may modulate neurodegenera-
(Lee et al., 2000). The precise causes of these aging-tive pathways in either a beneficial or a detrimental
associated alterations are unknown, but there is evi-fashion.
dence that reactive oxygen species may play an impor-Most neurodegenerative disorders are associated
tant role (Beckman and Ames, 1998; Prolla and Mattson,with the accumulation of abnormal protein assemblies
2001). It remains uncertain to what extent the inflamma-(proteopathies) (Orr and Zoghbi, 2000; Walker and Le-
tory changes associated with aging explain why aging isVine, 2000; Sherman and Goldberg, 2001), and increas-
an important risk factor for all major neurodegenerativeing evidence suggests that such protein assemblies can
diseases.be major triggers of cellular stress and neuroinflamma-
Chronic inflammation might be maintained by cellulartion (Figure 2). The formation of abnormal protein as-
distress signals emanating from neurons that survivesemblies in neurodegenerative diseases can result from
for prolonged periods despite the abnormal accumula-genetic mutations in specific proteins. Mutations in the
tion of proteins and significant injury to their presynapticgenes encoding human amyloid precursor protein
terminals or dendritic processes. Synaptic degeneration(hAPP) or presenilins 1 or 2, which cause early-onset
is indeed a prominent feature of neurodegenerative dis-Alzheimer’s disease (AD), result in abnormal proteolytic
eases and related transgenic models. For example, lossprocessing of hAPP, increasing the production and ex-
of synaptophysin-immunoreactive presynaptic termi-tracellular deposition of hAPP-derived amyloid  pep-
nals correlates well with cognitive decline in AD (De-tides (A) (Selkoe, 2001). Mutations in the genes encod-
Kosky and Scheff, 1990; Terry et al., 1991) and developsing the ubiquitin E3 ligase parkin or the de-ubiquinating
in hAPP transgenic mice well before A is depositedenzyme Uchl1 lead to familial Parkinson’s disease (PD)
into extracellular amyloid plaques (Mucke et al., 2000).(Chung et al., 2001). In most other neurodegenerative
The accumulation of nonfibrillar oligomeric A speciesdiseases, mutations promote abnormal folding and ag-
(Klein et al., 2001) in or around presynaptic terminalsgregation of the mutated proteins themselves (Sherman
might disrupt vesicle trafficking, transmitter release, andand Goldberg, 2001). In AD, mutations account for only
synaptic integrity. In addition, A might disrupt axonala small fraction of cases, suggesting that other factors
transport (Gunawardena and Goldstein, 2001), whichmust be responsible for the abnormal accumulation of
would also interfere with the maintenance of synapticA seen in the vast majority of patients with this disease.
contacts. Similar synaptic deficits could also contributeWhatever causes the extracellular deposition of A in
to PD (Masliah et al., 2000, 2001), since synapses arethe form of amyloid plaques in sporadic AD cases, this
highly enriched with -synuclein, the main componentprocess is clearly among the most notorious triggers of
of the intraneuronal Lewy bodies found in this condition.chronic inflammatory reactions in the CNS (Akiyama et
In experimental models of nerve injury, degeneratingal., 2000), and there is ample evidence from in vitro
studies that A aggregates can activate a variety of synapses trigger the rapid activation of astrocytes and
Review
421
Figure 2. Some Components of the Inflammatory Response to CNS Degeneration
Pathogenic triggers, such as accumulation of abnormal proteins in cells or extracellular spaces, elicit cellular stress responses and can result
in the progressive dysfunction and degeneration of neurons. Interactions indicated by arrows involve a large number of soluble factors.
Cytokines and other mediators of the innate immune response are released by astrocytes and microglia to orchestrate defense mechanisms
and initiate the removal or sequestration of the pathogenic triggers. A selection of molecules and receptors involved in the recognition of
abnormal proteins and degenerating cells is illustrated. Colors are used to indicate interactions between ligands and receptors. Abnormal
proteins and degenerating neurons are tagged by complement proteins such as C3b or C1q or by antibodies for recognition and phagocytosis
by glial cells. Degenerating neurons may also be phagocytosed if they display intercellular adhesion molecule-3 (ICAM-3), phosphatidyl serine
(PS), or oxidized lipids on their cell surface. Receptors on glial cells recognize these tags and initiate inflammatory responses. MHC molecules
might display abnormal proteins with novel antigenic epitopes to lymphocytes, resulting in acquired immune responses. C1qRp, C1q receptor
for phagocytosis; CR3, complement receptor 3; FcR, Fc receptor; PSR, phosphatidyl serine receptor; SR, scavenger receptor.
microglia and the release of inflammatory mediators cephalitis. There are also forms of cell death that com-
bine aspects of apoptosis and necrosis but do not fit(Aldskogius et al., 1999).
Degenerating cells can provoke inflammation until into either of these categories, including paraptosis
(Sperandio et al., 2000) and abortosis (Raina et al., 2001).they are cleared by phagocytes. Whether the death of
neurons and other CNS cells gives rise to inflammatory These forms of cell death may play important roles in
neurodegenerative disorders, but this remains to bereactions may depend, at least in large part, on how
they die. A particular type of programmed cell death, proven, and their relationship to inflammation has not
been defined.apoptosis, plays a key role in shaping the CNS during
development. If executed effectively, apoptosis results
in the uneventful removal of dying cells, with little or no Innate Immune Mechanisms
Triggers of inflammatory reactions can engage the im-inflammation (Sastry and Rao, 2000). Although apopto-
sis clearly occurs in neurodegenerative disorders, it re- mune system at multiple levels. To begin with, they re-
cruit the innate immune system. Subsequently, the ac-mains uncertain whether it accounts for most of the
neuronal loss and whether it can be executed flawlessly quired immune system may become involved also. The
responses of resident CNS cells to injury are in manyin these conditions (Cotman et al., 1999; Sperandio et
al., 2000; Green and Beere, 2001; Raina et al., 2001). respects related more closely to the innate than to the
acquired immune system. The innate immune systemA different type of cell death, necrosis, is almost al-
ways pathological and often triggers a prominent inflam- consists of phagocytes, natural killer cells, and mole-
cules that mediate local inflammatory responses or sup-matory reaction. Although necrotic cell death can occur
in neurodegenerative disorders, there is typically much port acquired immune responses (Figure 1). Compo-
nents of the innate immune system in the CNS includeless evidence for it in these conditions than in more
acute neurological diseases, such as stroke or viral en- microglia and astrocytes, which are strongly activated
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in most neurodegenerative diseases and produce a vari- discrepancy is uncertain, there is additional evidence
for a neuroprotective role of complement activation. Forety of inflammatory mediators and other injury response
factors (Eddleston and Mucke, 1993; Mennicken et al., example, C3a and C5a bind to specific receptors on
neurons (Nataf et al., 1999), and intraventricular infusion1999; Gasque et al., 2000; Akiyama et al., 2000; Nguyen
et al., 2002). of C5a protected mice against glutamate-induced neu-
rotoxicity (Osaka et al., 1999). This protection involvedMolecular Mediators
Innate immune responses are initiated by secreted mol- inhibition of caspase 3 by mitogen-activated protein ki-
nase (Mukherjee and Pasinetti, 2001). Naturally C5-defi-ecules such as collectins or defense collagens (Tenner,
1999), which recognize diverse cellular and tissue abnor- cient mice were more susceptible to excitotoxic lesions
than wild-type controls (Pasinetti et al., 1996). Perhapsmalities. Members of this group of proteins include sur-
factant protein A, calreticulin, and complement proteins even more surprising, sublytic concentrations of the
membrane attack complex protected oligodendrocytessuch as C1q and mannose binding lectin. All have a
collagen-like receptor binding domain and multiple and Schwann cells from apoptosis (Fishelson et al.,
2001). Finally, transgenic inhibition of C3 activation elic-globular domains that recognize pathogen-associated
molecular patterns on microbes, dying cells, and abnor- ited a 2- to 3-fold increase in A deposition and a promi-
nent accumulation of degenerating neurons in hAPPmal protein deposits (Tenner, 1999). Binding of col-
lectins to reactive surfaces can activate the complement transgenic mice (Wyss-Coray et al., 2002). These results
suggest a role of complement activation products incascade or mediate phagocytosis through the C1q re-
ceptor (Tenner, 1998). Besides the collectins, the com- protecting against A-induced neurodegeneration and
clearance of amyloid. They do not exclude the possibilityplement protein C3 seems also able to specifically acti-
vate the complement cascade when bound to amyloid that complement activation in neurodegenerative condi-
tions may also have detrimental consequences of com-deposits, extracellular DNA, and dying cells (Sahu and
Lambris, 2001; Fishelson et al., 2001). plement activation in neurodegenerative conditions
(Pasinetti, 1998; McGeer and McGeer, 1999; AkiyamaAlthough the liver is the major source of complement,
glial cells and neurons in the CNS can produce most et al., 2000).
Effector Cellsof the 30 different proteins that make up the complex
complement cascade. C1q, mannose binding lectin, and Microglia and astrocytes, the main effector cells of in-
nate immune responses in the CNS, are strongly acti-C3 stimulate the activation and chemotaxis of inflamma-
tory cells, promote phagocytosis, and facilitate lysis by vated in neurodegenerative diseases, producing an
array of inflammatory mediators and fulfilling phagocyticthe membrane attack complex (Holers, 1996; Song et
al., 2000). Levels of complement components are in- functions (Eddleston and Mucke, 1993; Aldskogius et al.,
1999; Benveniste et al., 2001). Microglia appear to be re-creased in AD (Gasque et al., 2000; Akiyama et al., 2000),
PD (Yamada et al., 1992), and Huntington’s disease (HD) sponsible for more generalized phagocytosis involving ac-
tivation of the complement cascade, whereas astrocytes(Singhrao, 1999). Complement activation products, in-
cluding the membrane attack complex, colocalize with have been implicated in circumscribed phagocytic pro-
cesses, such as the removal of individual synapses.amyloid plaques and tangle-bearing neurons in AD
(Webster et al., 1997b) and Down’s syndrome (Stoltzner Axotomy-induced synaptic degeneration in various ex-
perimental models results in rapid activation of microgliaet al., 2000; Head et al., 2001). Using differential mRNA
display, C1q B-chain mRNA was found to be strongly and astrocytes and subsequent elimination of damaged
synapses (Kreutzberg, 1996; Aldskogius et al., 1999).increased in an experimental model of prion disease
(Dandoy-Dron et al., 1998). The idea that imbalances between protective and de-
structive functions of microglia and astrocytes mightWhat might be the consequences of complement acti-
vation in the degenerating CNS? Complement activation contribute to neuronal or synaptic damage in neurode-
generative disease has appeal but remains to be provencan lead to the formation of C3 convertases, multiprotein
enzyme complexes that cleave the secreted comple- experimentally.
Other effector cells of the innate immune system in-ment factor C3 into C3a and C3b (Sahu and Lambris,
2001). C3a can promote chemotaxis of phagocytic cells. clude nonclassical lymphocytes such as natural killer
cells. These cells accumulate around degeneratingC3b binds covalently to acceptor molecules, initiating
formation of the membrane attack complex and cell nerve fibers and phagocytes in the axotomized facial
motor nucleus (Raivich et al., 1998), demonstrating theirlysis. Alternatively, C3b deposition mediates phagocyto-
sis through complement receptors on macrophages/ ability to enter the brain and suggesting a potential role
in neurodegeneration. Antigen-specific receptors onmicroglia. Host cells are normally protected from spon-
taneous complement activation and self attack by a natural killer cells are less diverse than T cell receptors
(TCRs), but some of them can interact with a limitednumber of soluble or membrane-bound complement
regulatory proteins (Holers, 1996). Whether complement number of MHC molecules (Bromley et al., 2001). Signal-
ing of natural killer cell receptors is mediated by CD3activation in neurodegenerative disorders represents an
appropriate injury response or results from an impair- or by DAP-12 and other receptor-associated proteins
with immunoreceptor tyrosine-based activation motifsment of these regulatory systems remains to be deter-
mined. in their cytoplasmic domain (Lanier and Bakker, 2000).
Intriguingly, a loss-of-function mutation in DAP12 causesIn transgenic mouse models of immune-mediated
CNS disease, inhibiting C3 complement activation de- Nasu-Hakola disease, a presenile frontal dementia asso-
ciated with axonal degeneration, widespread microg-creased disease severity (Davoust et al., 1999). In con-
trast, eliminating C3 expression increased disease se- liosis, and microvascular degeneration (Paloneva et al.,
2000). Thus, impaired function of natural killer cell recep-verity (Calida et al., 2001). Although the reason for this
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tors or possibly of natural killer cells may lead to inflam- phagocytic engulfment are mutated (Reddien et al.,
2001; Hoeppner et al., 2001). This finding suggests thatmation and degeneration of the CNS.
Probably the most efficient and aggressive phago- phagocytes can deliver the lethal hit to cells undergoing
apoptosis and that cells can retreat from this cell deathcytes in the CNS are round or ameboid microglia, which
express high levels of macrophage markers; in contrast, program. In neurodegenerative diseases, potent survival
factors may counteract proapoptotic signals (Hoeppnerramified (putatively resting) microglia have little phago-
cytic activity (Kreutzberg, 1996). Microglia associated et al., 2001), giving phagocytic microglia the power to
determine whether injured neurons live or die.with highly fibrillar amyloid plaques in AD brains show
a ramified morphology even though they express activa- Much progress has been made in identifying factors
involved in phagocytosis (Figure 2); they can be groupedtion markers (Dickson et al., 1993), suggesting that they
might be nonphagocytic (DeWitt et al., 1998). However, into three broad categories. (1) Flags or “eat me” signals
are expressed by dying cells, including phosphatidylser-upon activation in cell culture, microglia can ingest and
degrade A aggregates (Brazil et al., 2000; Wyss-Coray ine, intracellular adhesion molecule-3, oxidized phos-
pholipids, and altered carbohydrates (Giles et al., 2000;et al., 2001; Webster et al., 2001) or amyloid plaque
cores from AD brains (DeWitt et al., 1998). Astrocytes Savill and Fadok, 2000; Hengartner, 2001). (2) Recogni-
tion or tethering molecules, some of which may havemay also participate in the phagocytosis of A, either
directly (Shaffer et al., 1995) (J. Huseman and T.W.-C., signaling function, can be expressed at the surface of
phagocytic cells. They include scavenger receptors, theunpublished data) or by regulating microglial activities
(DeWitt et al., 1998). vitronectin receptor, complement receptors, the phos-
phatidylserine receptor, the receptor tyrosine kinaseAmyloid fibrils have been detected in microglia of AD
brains (Wegiel and Wisniewski, 1990; Frackowiak et al., Mer and related family members (Scott et al., 2001; Lu
and Lemke, 2001), the lipopolysaccharide (LPS) recep-1992), and injection of fibrillar A in rat brains resulted
in a rapid accumulation of A immunoreactivity in peri- tor CD14 (Devitt et al., 1998), and calreticulin in combina-
tion with the low-density lipoprotein receptor-relatedvascular microglia (Frautschy et al., 1992). After vaccina-
tion of aged hAPP transgenic mice with A, their amyloid protein (Ogden et al., 2001). Collectins and complement
C3 are soluble recognition molecules that are secretedburden was reduced, and A colocalized with activated
microglia in the brain (Schenk et al., 1999). Subsequent by phagocytic cells and can mediate interactions of
dying cells with phagocytes (Mevorach et al., 1998).studies suggested that A is cleared by microglia
through Fc receptor-mediated phagocytosis (Bard et al., (3) Molecules involved in intracellular signaling in the
phagocytic cell may participate in cytoskeletal reorgani-2000). Consistent with these findings, activated micro-
glia accumulated around A deposits after topical ad- zation and handling of ingested material. Genetic analy-
sis in C. elegans has identified at least seven moleculesministration of anti-A antibodies in live mice (Bacskai
et al., 2001). Increased microglial activation was also in this category which appear to function in the removal
of apoptotic or necrotic cells during larval developmentassociated with reduced A accumulation in hAPP trans-
genic mice overproducing the cytokine transforming (Hengartner, 2001). Phagocytes in C. elegans can esca-
late programmed cell death by activating the caspasegrowth factor 1 (TGF-1) (Wyss-Coray et al., 2001) and
in hAPP/presenilin 1 doubly transgenic mice treated with ced-3 (Reddien et al., 2001; Hoeppner et al., 2001), pos-
sibly to ensure that dying cells do not recover.an antiinflammatory drug (Jantzen et al., 2002).
An alternative mechanism for the antibody-induced Intriguing evidence has been emerging that deficient
phagocytosis might promote inflammation. Phagocytesclearance of cerebral amyloid has recently been pro-
posed (DeMattos et al., 2001, 2002). Infusion of anti-A engaged in the removal of apoptotic cells release antiin-
flammatory molecules, including interleukin-10, TGF-1,antibodies elicited a rapid rise in antibody-bound A in
the plasma. Based on this finding and ancillary evidence, lipoxins, and prostaglandin E2, and suppress the syn-
thesis of proinflammatory factors such as tumor necro-the authors concluded that anti-A antibodies might
create a peripheral sink that augments a putative A sis factor  (TNF-) (Voll et al., 1997; Fadok et al., 1998,
2000; McDonald et al., 1999; Godson et al., 2000). Somegradient between brain and blood “drawing” A out of
the brain parenchyma. Consistent with this notion, the of these antiinflammatory responses appear to depend
on specific signals that emanate from apoptotic cellsextent of the antibody-induced surge in peripheral A
levels correlated with the cerebral amyloid burden (De- and are recognized by receptors on phagocytes. For
example, the binding of apoptotic cells to CD14 on mac-Mattos et al., 2001, 2002). It is also conceivable that the
infusion of certain anti-A preparations increases the rophages reduces TNF- production, even though bind-
ing of this receptor by LPS or bacteria results in a proin-half-life of A in the blood or induces a transient alter-
ation of the blood-brain barrier, which could promote flammatory response of the macrophage (Devitt et al.,
1998). The antiinflammatory cytokine TGF-1 is se-the leakage or transport of A from the brain into the
blood. These possibilities are not mutually exclusive and creted directly from apoptotic cells, suppressing the
release of inflammatory cytokines from macrophages incan be further tested experimentally.
Corpse Removal culture (Chen et al., 2001).
Studies of mutant mice lacking complement proteinsMicroglia and other phagocytes participate not only in
the degradation of abnormal protein deposits and invad- suggest that deficient phagocytosis can indeed lead to
immune-mediated tissue degeneration and inflamma-ing microbes, but also in the removal of degenerating
host cells. Indeed, cell death and phagocytosis are often tion in vivo (Botto et al., 1998; Taylor et al., 2000). Mice
deficient in C1q developed glomerulonephritis associ-intricately linked (Giles et al., 2000; Savill and Fadok,
2000). In Caenorhabditis elegans, for example, cells that ated with apoptotic bodies (Botto et al., 1998). Defi-
ciency of C1q, and to a lesser extent of C4, also reducedare programmed to die survive if genes involved in
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the clearance of apoptotic cells injected into the perito- by cytokines or neural injury. Neuronal populations af-
fected by amyotrophic lateral sclerosis (ALS) or PD inneum (Taylor et al., 2000). Mice lacking the tyrosine
humans increase their expression of MHC class I mole-kinase receptor Mer were blind and showed spontane-
cules in response to axotomy or interferon- stimulationous accumulation of apoptotic cells in peripheral tis-
in rats (Linda et al., 1998, 1999).sues, presumably due to a reduced ability of macro-
MHC class I expression on neurons is also regulatedphages to phagocytose apoptotic cells (Scott et al.,
by electrical activity, and polymorphic variants of these2001). Mice lacking all three members of this kinase
molecules are expressed in unique subsets of neuronsfamily (Mer, Axl, and Tyro3) were viable but showed
throughout the mature CNS (Neumann et al., 1997; Corri-increased apoptosis and accumulation of degenerating
veau et al., 1998; Linda et al., 1998). Expression of MHCcells in peripheral tissues and in the hippocampus, cere-
class I and 2-microglobulin mRNAs is markedly in-bellum, and neocortex (Lu et al., 1999; Lu and Lemke,
creased in tetrodotoxin-silenced neurons. CD3, an2001). Notably, missense mutations in Mer cause retinal
adaptor molecule associated with the TCR and NK celldegeneration in rats (D’Cruz et al., 2000) and retinitis
antigen receptors, was also increased in the silencedpigmentosa in humans (Gal et al., 2000), suggesting that
neurons. Subsequent studies in mice lacking functionaldefective phagocytosis can lead to inflammation and
MHC class I or CD3 demonstrated that both moleculesneurodegeneration in the CNS of both rodents and
are involved in CNS development and plasticity (Huh ethumans.
al., 2000). The authors proposed that MHC class I acting
at the neuronal synapse participates in activity-depen-Acquired Immune Mechanisms
dent elimination or refinement of synaptic connectionsAlthough some inflammatory responses are present in
and that the related signal transduction is mediated byinsects and annelid worms, the core component of in-
CD3 and its associated kinase Fyn, which is importantnate immunity, the complement system, first appeared
in neural plasticity (Kojima et al., 1997).in echinoderms (Zarkadis et al., 2001). Only vertebrates
In neurodegenerative disorders, novel and potentiallyalso developed acquired immunity, which is based on
antigenic peptides may be derived from mutated orgene rearrangement of immune receptors (Finch and
modified proteins or generated by abnormalities in theMarchalonis, 1996). Acquired immunity results in immu-
proteasomal pathway. Although such peptides could,nological memory through the production of immuno-
in principle, be displayed to immune cells by neuronalglobulins and lymphocytes (mainly T cells and B cells)
MHC molecules (Figure 2), there is no convincing evi-carrying binding sites for specific antigens. That such
dence in neurodegenerative disorders that neurons areimmune responses could, in principle, contribute to neu-
a direct target for attack by cytotoxic T lymphocytes.rodegenerative disorders is suggested by studies on
In contrast to MHC class I molecules, MHC class IIother disease states. For example, in transgenic mice
molecules present peptides to immune cells that areexpressing the human CD4 receptor on microglia/mac-
derived primarily from extracellular antigens taken uprophages, peripheral immune responses can trigger
into the endosomal/lysosomal pathway by phagocyto-subacute neurodegeneration independent of CNS infil-
sis, receptor-mediated endocytosis, or macropino-
tration by immune cells, and this process may be rele-
cytosis (Watts, 1997). The resulting complexes engage
vant to some forms of HIV-associated dementia (Buttini
specific TCRs on CD4-bearing T cells. Increased expres-
et al., 1998). Antibodies directed against neuronal anti-
sion of MHC class II molecules is a classical marker of
gens may elicit neuronal dysfunction and neurodegener- microglial cell activation. Microglial MHC class II expres-
ation in stiff-person syndrome and various paraneoplas- sion is prominently increased in AD in association with
tic syndromes, while both antibodies and cytotoxic T amyloid plaques and degenerating neurons and in PD
cells may be involved in the loss of neurons observed around degenerating dopaminergic neurons in the sub-
in Rasmussen’s encephalitis (Whitney and McNamara, stantia nigra (McGeer et al., 1987; Akiyama et al., 2000).
1999; Archelos and Hartung, 2000; Bien et al., 2002). Because MHC molecules appear not to be expressed
The Expanding Role of MHC Molecules at the cell surface in the absence of peptides (Watts,
Acquired cellular immunity has evolved to survey the 1997; Pamer and Cresswell, 1998), increased MHC ex-
body for abnormal proteins, either foreign or altered self. pression may reflect increased peptide presentation.
This remarkably complex task is carried out by T cells, But what peptides might be presented in neurodegener-
which interrogate and recognize the proteinaceous con- ative disease? Components of self proteins with abnor-
tent of cells at the so-called immunological synapse mal conformations? Autoantigens released from dam-
(Donnadieu et al., 2001; Bromley et al., 2001). Like the aged cells? Could interactions between microglia and
neuronal synapse, this structure supports the focal ex- T lymphocytes trigger pathogenic immune responses in
change of information between two cells across a spe- the degenerating CNS? The answers to these questions
cialized membrane structure. At the center of the immu- are unknown.
nological synapse are the MHC molecules and the T Lymphocyte Invasion of the CNS
cell receptor. MHC class I molecules, together with 2- In patients with neurodegenerative diseases, T cells do
microglobulin, associate with peptides generated pri- not typically accumulate in significant numbers in the
marily from intracellular proteins by proteolytic degrada- brain. However, there is evidence for more subtle T cell
tion in the proteasome. At the cell surface, peptides are alterations. For example, T cell activation by A and
recognized in the context of MHC molecules by specific other APP-derived peptides is reduced in AD cases
TCRs on T cells expressing the CD8 accessory molecule compared with nondemented controls (Trieb et al.,
(Pamer and Cresswell, 1998). MHC class I molecules 1996). T cells from hAPP transgenic mice also respond
poorly to A but normally to other antigens, indicatingare present on all cell types and can be upmodulated
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the induction of relative T cell tolerance to A (Monso- ies directed at neuronal antigens appear to play a causal
nego et al., 2001). In contrast, blood levels of activated role (Whitney and McNamara, 1999; Archelos and Har-
CD4-positive T cells were significantly higher in patients tung, 2000; Bien et al., 2002).
with PD and rats with PD-related neurodegeneration In line with the double-edged sword theme of this
(Fiszer et al., 1994; Bas et al., 2001). Lymphocytic infil- Review, antibody responses may also have beneficial
trates and antibody deposits have been detected in effects in neurodegenerative diseases. For example, they
postmortem CNS tissues from cases with familial or can trigger or mediate the removal of potential neuro-
sporadic ALS (Troost et al., 1989; Kawamata et al., 1992). toxic protein aggregates. The vaccination-induced gen-
Proinflammatory changes in the CNS, including upregu- eration of antibodies against A prevented and partially
lation of intercellular adhesion molecule-1 and accumu- reversed AD-like pathological alterations and behavioral
lation of immunoglobulins, preceded clinical disease deficits in hAPP transgenic mice (Schenk et al., 1999;
manifestations in superoxide dismutase 1 transgenic Janus et al., 2000; Morgan et al., 2000). The observation
mice, a model of ALS (Alexianu et al., 2001). Moreover, that AD patients have lower levels of anti-A antibodies
clonal expansion and activation of peripheral T cells was in the CSF than nondemented controls (Du et al., 2001)
observed in patients with ALS or progressive muscular raises the possibilities of antibody sequestration by A
atrophy (Katchar et al., 2001), supporting the notion that and of AD-related alterations in the response of B cells.
autoreactive T cells may be involved in motor neuron
disease. Names and Functions versus Roles
The pathophysiological role and significance of these of Inflammatory Mediators
aberrant T cell reactions is not clear, since both CD4- Given the multiple functions of inflammatory factors,
and CD8-positive T cells can have detrimental or protec- it is often difficult to determine their roles in specific
tive effects on the CNS. Cultured murine hippocampal pathophysiological situations. Cytokines and chemo-
neurons induced to express MHC class I molecules and kines are key regulators of inflammatory processes and
pulsed with a viral peptide were rapidly damaged by have been implicated in the pathogenesis of neurode-
virus-specific cytotoxic T cells (Medana et al., 2001). generative diseases (Mennicken et al., 1999; Akiyama
Damage was most prominent in neurites and included et al., 2000; Allan and Rothwell, 2001). They regulate the
cytoskeletal breaks and the formation of neuritic spher- activity and survival of inflammatory cells and mediate
oids, whereas the neuronal soma seemed to remain the communication of immune cells with each other and
intact. In contrast, T cells recognizing self antigens may with other cells of the body. Thus, the functions of these
contribute to tissue repair after neuronal injury (Schwartz molecules in the immune system resemble those of neu-
et al., 1999; Hohlfeld et al., 2000). When transferred into rotrophins and neuromodulators in the CNS. In fact,
mice after optic nerve crush injury, activated myelin ba- there is evidence for functional overlap between these
sic protein-specific T cells protected neurons from de- groups of molecules. Neurons carry receptors for many
generation (Moalem et al., 1999). In the same model, cytokines and chemokines, suggesting an active cross-
induction of beneficial autoreactive T cells significantly talk between the immune and nervous system. The che-
enhanced the survival of retinal ganglion cells (Kipnis
mokine fractalkine is expressed at higher levels in the
et al., 2001). Furthermore, genetic ablation of T and B
CNS than in the periphery and has become known more
lymphocytes in TNF- transgenic mice worsened neuro-
recently as neurotactin (Mennicken et al., 1999). Many
degeneration and clinical signs (Stalder et al., 1998).
cytokines have neurotrophic effects and function in CNSSome of these findings may relate to the ability of autore-
development, and classical neurotrophins are also pro-active CD4- or CD8-positive T cells to secrete neuro-
duced by lymphocytes (Ehrhard et al., 1993; Kerschen-trophins (Ehrhard et al., 1993). For example, myelin basic
steiner et al., 1999).protein-specific T cells stimulated with antigen in vitro
Results obtained in genetically modified mouse mod-secreted brain-derived neurotrophic factor, and inflam-
els of CNS diseases suggest that altered expression ofmatory CNS infiltrates in human cases with multiple scle-
specific inflammatory factors may trigger or modulaterosis or disseminated autoimmune encephalomyelitis
the development of neurodegenerative disease. Neu-were immunoreactive for this factor (Kerschensteiner et
ronal apoptosis and cognitive deficits were identified inal., 1999).
mice with neuronal overexpression of COX-2, an enzymeAutoantibodies—Culprits, Bystanders,
involved in the first steps of prostanoid synthesis (An-or Protectors?
dreasson et al., 2001) and the main target of the latestAt least 50 reports in the literature describe antibodies
class of nonsteroidal antiinflammatory drugs (NSAIDs)against various CNS antigens in sera from AD patients.
(Zandi and Breitner, 2001). Astroglial overexpression ofAutoantibodies against CNS antigens have also been
TNF-, interferon-, or interleukin-6 resulted in neurode-reported in HD, Creutzfeldt-Jacob disease, ALS, and PD
generation, gliosis, and progressive neurological dis-(Toh et al., 1985; Defazio et al., 1994; Leblhuber et al.,
ease (Campbell et al., 1993; Akwa et al., 1998). The1998; Yi et al., 2000). Although the pathophysiological
disease in TNF- transgenic mice was even more pro-significance of these antibodies is unclear, they provide
nounced when they lacked mature T or B lymphocytes,evidence of crosstalk between the degenerating CNS
suggesting indirectly that microglia/macrophages areand the immune system. Many of these antibodies may
responsible for the pathogenic inflammatory processoriginate in the periphery and enter the brain where the
(Stalder et al., 1998). Surprisingly, mice lacking the re-blood-brain barrier is leaky, but antibodies can also be
ceptor for TNF- were more susceptible to ischemiaproduced locally by B cells that have entered the CNS or
and excitotoxic injury (Bruce et al., 1996; Sullivan et al.,the subarachnoid space (Knopf et al., 1998). As outlined
above, there are neurological diseases in which antibod- 1999), underlining how difficult it might be to predict the
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outcome of therapeutic manipulations aimed at these
molecules.
Even cytokines that likely fulfill primarily beneficial
functions when expressed during acute phases of
wound repair can have complex, including detrimental,
effects if overexpressed for prolonged periods. For ex-
ample, TGF-1 is a major organizer of wound repair
(Finch et al., 1993). However, TGF-1 mRNA levels in
postmortem AD brains correlated positively with the ex-
tent of cerebral amyloid angiopathy, and constitutive
overexpression of TGF-1 from astrocytes resulted in
the deposition of A in blood vessels in hAPP transgenic
mice (Wyss-Coray et al., 1997, 2001). In contrast, overex-
pression of TGF-1 diminished plaque formation in the
brain parenchyma and reduced overall A accumulation
more than 50% (Wyss-Coray et al., 2001). This was asso-
ciated with a prominent microgliosis, and in cell culture,
TGF-1 promoted microglial degradation of A (Wyss-
Coray et al., 2001). More recent studies showed that
Figure 3. Turning the Right Side of the Inflammatory Sword
TGF-1 overexpression increased the synthesis of C3 in against AD
hAPP transgenic mice and that inhibition of complement Neurotoxic assemblies of A peptides (gray wavy lines) presumably
activation increased A accumulation 2- to 3-fold. Com- injure neurons and activate glia in AD brains. While some glial prod-
plement inhibition in these mice was also associated ucts can be neurotoxic, other glial products and activities protect
neurons and help remove A aggregates. Treatment with NSAIDswith a prominent accumulation of degenerating neurons
or vaccination with A appears to tip the balance from detrimentalin the hippocampus (Wyss-Coray et al., 2002). These
to beneficial glial activities and inhibits the accumulation of A instudies suggest that at least some components of the
the brain. NSAIDs, nonsteroidal antiinflammatory drugs. Detrimental
complement cascade fulfill neuroprotective roles in effects are depicted in red, beneficial effects in green.
mice.
The findings reviewed above underline the importance
of differentiating between the function(s) a molecule can genic mice with the NSAID ibuprofen reduced A accu-
fulfill and the specific role it plays in a particular disease. mulation, proinflammatory cytokine production, and
The latter may depend critically on where, when, for microglial activation around plaques (Lim et al., 2000).
how long, and in what context the molecule is produced. Similarly, treatment with NO-flurbiprofen, a nitric oxide-
Because of the multifunctionality of many inflammatory donating NSAID, celcoxib, a COX-2 antagonist, or ibu-
molecules, their altered CNS expression does not nec- profen also resulted in reduced A deposition in hAPP/
essarily imply the presence of an inflammatory or im- presenilin-1 doubly transgenic mice (Jantzen et al.,
mune-mediated process in the CNS. This differentiation 2002). NO-flurbiprofen, which had the strongest inhibi-
has implications for the design of better treatments for tory effect on A accumulation, resulted in a striking
neurodegenerative disorders. activation of microglia in hAPP/presenilin-1 transgenic
mice but not in nontransgenic controls (Jantzen et al.,
2002). NO-flurbiprofen also increased microgliosis inTo Suppress or to Direct the
Inflammatory Machinery aged rats that had been chronically infused with LPS but
not in similarly treated young rats (Hauss-Wegrzyniak etThe ultimate proof that a suspected process contributes
critically to a disease would ideally come from human al., 1999), indicating that microglia may respond differ-
ently to NSAIDs depending on age and the presence oftrials in which the pathogenic process is blocked effec-
tively and specifically. Unfortunately, it is not always other inflammatory triggers in the brain.
The link between NSAID use and reduced AD risk haseasy to assess how effectively a suspected pathogenic
process was blocked in individual patients, and many been interpreted as evidence for a causal link between
brain inflammation and AD (McGeer et al., 1996; Stewartcompounds have numerous actions besides those for
which they are prescribed. For example, tetracyclines, et al., 1997; Pasinetti, 1998). The recent findings by Weg-
gen et al., 2001, raise the possibility that the observedwhich are frequently used to treat infections in humans
(and to regulate transgene expression in mice), have not association is due, at least in part, to a reduction in A
levels. Ongoing trials should reveal whether NSAIDs withonly antimicrobial but also antiinflammatory and antioxi-
dant activities (Yrja¨nheikki et al., 1999; Chen et al., 2000; A-reducing capacity can prevent or stall the develop-
ment of AD. No significant effects were observed on theTikka et al., 2001). Even more pertinent to this review is
the recent finding that certain NSAIDs inhibit the produc- progression of AD in treatment trials with a variety of
compounds that strongly suppress inflammation, in-tion of A (Figure 3) independently of COX, the main
pharmacological target of these drugs (Weggen et al., cluding corticosteroids (Aisen, 2000), diclofenac/miso-
prostol (Scharf et al., 1999), COX-2 inhibitors (Zandi and2001). This observation is particularly intriguing in light
of the many epidemiological studies demonstrating an Breitner, 2001), and hydroxychloroquine (Van Gool et
al., 2001).association between the use of NSAIDs and reduced
AD risk (McGeer et al., 1996; Zandi and Breitner, 2001). Thus, it remains uncertain to what extent inhibiting
inflammation can reduce neurodegenerative disease. InIn line with these reports, treatment of hAPP trans-
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fact, several recent findings suggest that specific inflam- coding cytokines or other injury response factors (Mah-
matory responses may be beneficial. For example, inhib- ley and Huang, 1999; McGeer and McGeer, 2001).
iting the activation of C3 complement component in-
creased, rather than decreased, A deposition and Conclusions
neurodegeneration in hAPP transgenic mice (Wyss- Neurodegenerative disorders are associated with a vari-
Coray et al., 2002). Eliciting a vigorous antibody re- ety of inflammatory responses whose precise roles in
sponse to A in hAPP transgenic mice prevented and these conditions remain to be defined. Much more
partially reversed AD-like pathology and behavioral defi- needs to be learned in general about the functions of
cits (Schenk et al., 1999; Janus et al., 2000; Morgan inflammatory and immune molecules in the normal and
et al., 2000). These findings propelled this therapeutic diseased CNS. A better understanding of specific mo-
strategy into the clinic, where it recently met with obsta- lecular pathways in activated glial cells may help recon-
cles that highlight the double-edged sword of inflamma- cile apparently contradictory outcomes of inflammatory
tion (Senior, 2002). In a phase I trial, 64 patients received responses. Since many of these responses can exert
six to eight doses of the A vaccine, and no significant potent beneficial effects, directing and instructing the
immunological side effects were observed. However, in inflammatory machinery may be a better therapeutic
a subsequent phase II trial, in which 300 patients re- objective than suppressing it. It is interesting to note in
ceived one to three doses of the vaccine (in a slightly this context that the immune system and the CNS are
different formulation), 15 developed signs and symp- shaped by both genetic and environmental determi-
toms consistent with meningoencephalitis. None of 75 nants. Therefore, optimizing immune modulatory treat-
additional placebo control cases developed such side ments for neurological diseases may require detailed
effects. It is likely that the vaccine-induced complica- information not only on the genome but also on the
tions relate to the immunologic diversity of the immu- proteome of individual patients.
nized AD population.
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